IMM:ASX
Immutep Ltd
A$0.056
arrow_upward
+27.27%(+0.012) 1D
Sep 11, 4:19:19 PM GMT+10 · AUD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMM...
Open
A$0.05
High
A$0.06
Low
A$0.04
Mkt. cap
90.78M
Avg. vol.
4.90M
Volume
45.82M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
Open
A$0.05
High
A$0.06
Low
A$0.04
Mkt. cap
90.78M
Avg. vol.
4.90M
Volume
45.82M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.05
Shares outstanding
1.47B
No. of employees
19
News stories
From web sources and news partners
Simply Wall Street
·
1 day ago
Broker Revenue Forecasts For Immutep Limited (ASX:IMM) Are Surging Higher
Yahoo Finance
·
1 day ago
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
TipRanks
·
1 day ago
Immutep Refocuses Efti Development After Manufacturing Probe
https://www.dars.gov.et/
·
3 weeks ago
Immutep (IMMP) Stock: Ends Down by 0.84% at $0.39 in Latest Trading; Immediate View
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd